(lp0
S"Here's Why Alnylam Pharmaceuticals, Inc. Stock Bounced Up 10.1% Today Motley Fool - Feb 27, 2017 Shares of Alnylam Pharmaceuticals, Inc.  a clinical-stage biotech, notched a 10.1% gain to end Monday's session.Alnylam Pharmaceuticals Inc. - Receive News &amp; Ratings Daily - Chaffey BreezeWhy Analysts put forward these two stocks: Alnylam Pharmaceuticals, Inc. (ALNY ... - The USA Commerce"
p1
aS"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. Motley Fool - Feb 20, 2017 Late last year, Alnylam Pharmaceuticals, Inc.  took a big hit when the company scuttled an important development program because of safety concerns.Investors Alert -Alnylam Pharmaceuticals, Inc.'s  - Hot Stocks PointAlnylam Pharmaceuticals, Inc.  Updated Broker Ratings - NewsDen"
p2
aS'Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It Motley Fool - Feb 9, 2017 The Medicines Company  presented more positive data for their cholesterol-lowering drug inclisiran, which was called ALN-PCSsc before Alnylam out-licensed the drug. The Medicines Company is running a new phase 2 trial in patients with&nbsp;...Alnylam Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 09 - Equities.comAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial ... - Business Wire '
p3
aS'Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Feb 6, 2017 Agenus  and Alnylam Pharmaceuticals  are both clinical-stage biotechs developing drugs that hold the potential to make a big difference for patients.'
p4
aS"Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data Motley Fool - Nov 4, 2016 Alnylam Pharmaceuticals  fell 12.6% on Thursday after reporting earnings Wednesday afternoon, but it's recovered some of that today."
p5
aS'Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October Motley Fool - Nov 7, 2016 Shares of RNA interference hopeful Alnylam Pharmaceuticals, Inc.  took a 47.5% leap downward in October, according to data from S&amp;P Global Market Intelligence.'
p6
aS"What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure? Motley Fool - Oct 7, 2016 Alnylam Pharmaceuticals  announced on Oct. 5 that it was discontinuing development of revusiran in treating hereditary ATTR amyloidosis with cardiomyopathy .Alnylam Plunges 42% After Ending Development of a Key Medicine - BloombergAlnylam shares lose half their value as drug trial is halted - The Boston Globe"
p7
aS"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc. Motley Fool - Oct 10, 2016 Sarepta Therapeutics  now has an FDA-approved drug, while Alnylam Pharmaceuticals  doesn't and even recently experienced major clinical setback."
p8
aS'Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Sep 24, 2016 Clinical-stage biotechs Ziopharm Oncology  and Alnylam Pharmaceuticals , for example, have both suffered in 2016.'
p9
aS'Alnylam Pharmaceuticals Inc Risk Points versus Health Care CML News - 10 hours ago This is a scatter plot analysis of the critical risk points from the option market for Alnylam Pharmaceuticals Inc  compared to its own past and the Health Care ETF.'
p10
a.